Shanghai Henlius Biotech, Inc. announced that, recently, the recombinant humanised IgG2 anti-c-MET monoclonal antibody for injection HLX55 ("HLX55") has demonstrated its good safety and tolerability in a Phase 1 clinical trial for subjects with advanced solid tumours refractory to standard therapy. And the relevant clinical study report has been finished recently. The study is an open-label, multi-centre, dose finding/expansion Phase 1 clinical trial, primarily aimed (i) in the first stage, to evaluate the safety of HLX55 in patients with advanced or metastatic solid tumours refractory to standard therapy and to identify the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose, and (ii) in the second stage, to further investigate the efficacy and safety of HLX55 in patients with advanced or metastatic solid tumours with histologically confirmed cellular-mesenchymal epithelial transition factor (c-MET) mutations, amplification or overexpression and refractory to standard therapy. No dose-limiting toxicity (DLT) was reported on subject and neither serious adverse event nor MTD was observed in any dose group of the clinical trial. The results of the clinical trial demonstrated good safety and tolerability for HLX55.